# Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC

> **NCT06177015** · PHASE3 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 200 (estimated)

## Conditions studied

- Metastatic Prostate Cancer
- Intermitent Anti-androgen Therapy

## Interventions

- **DRUG:** Darolutamide continuous
- **DRUG:** Darolutamide intermittent

## Key facts

- **NCT ID:** NCT06177015
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06177015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06177015, "Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06177015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*